“The fibromyalgia community, comprised of patients and their families and support groups, has been waiting for a new drug for over 15 years. Analysis of insurance claims in the U.S ...

The CEO of Tonix, Dr. Seth Lederman, expressed optimism about the potential of TNX-102 SL to become the first new drug class for fibromyalgia management in over 15 years, highlighting the drug's ...

Disturbed sleep is a prominent feature of fibromyalgia symptomatology and has been proposed as one of the core symptoms that should be systematically assessed in clinical trials for the treatment ...